Gilead Sciences Releases Favorable Hepatitus C Data
publication date: Feb 3, 2012
Gilead Sciences reported fourth-quarter results and released favorable hepatitus C data for its all-oral regimen to treat the virus, and the shares are rallying nearly 10% on the promising news. The firm has now converged to our $54 per share fair value estimate.
To gain access to the members only content, click here to subscribe. You will be given immediate access to premium content on the site.